For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 3,161,064 | 2,565,982 | ||
| General and administrative | 1,400,136 | 1,655,152 | ||
| Total operating expenses | 4,561,200 | 4,221,134 | ||
| Operating loss | -4,561,200 | -4,221,134 | ||
| Change in fair value of warrant liabilities | 279,161 | 161,714 | ||
| Grant income | 22,174 | 153,685 | ||
| Currency exchange gain (loss) | -32,051 | -47,487 | ||
| Interest income | 147 | 148 | ||
| Interest expense | 5,960 | - | ||
| Total other income (expense) | -294,851 | -55,368 | ||
| Net loss attributable to common stockholders | -4,856,051 | -4,276,502 | ||
| Basic EPS | -5.82 | -5.13 | ||
| Diluted EPS | -5.82 | -5.13 | ||
| Basic Average Shares | 833,683 | 833,654 | ||
| Diluted Average Shares | 833,683 | 833,654 | ||
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)